Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. But if that doctor has access to information from 40,000 patients it’s a different story.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Oil for Medical Conditions CBD oil has gained popularity as a versatile and accessible option for managing various medical conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 28, 2021

More information about the organization is available at [link]. MAPS PBC strives to continually improve upon the supportive, equitable and accessible work environment. Ensure tracking and archiving of regulatory documentation lifecycle: submissions, correspondence, and related information for various regulatory applications.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

The Cannigma

FEBRUARY 2, 2021

Patients can also access CBD products without a prescription through local pharmacies. We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”. Interest among patients is high, but knowledge is limited.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. For more information, visit www.Chemistree.ca. (CSE: CHM) (CSE: CHM.WT) (OTCQB: CHMJF ) (the “Company” or “Chemistree”) is pleased to confirm that investee company ImmunoFlex Therapeutics Inc.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. POPLAR will focus on promoting safety, innovation, and equity in psychedelics research, commerce, and therapeutics. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries. Background.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

AUGUST 19, 2019

Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. This is at least due to the difficulty and cost involved in accessing a legal prescription. Patient access pathways.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Different types of research studies provide us with different types of information. What makes a good research study, anyway?

Research and Development 108

Research and Development Data THC Clinical Trials 108

TheAnswerPage

JANUARY 11, 2022

In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. to take a medical marijuana course that reviews the endocannabinoid system and the therapeutic use of marijuana.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

AUGUST 31, 2020

He was exposed to alternative herbal options during his volunteer work as a Spanish interpreter at migrant clinics, and he became interested in medical cannabis when his mother asked him about CBD oil and cannabis as alternative options for her daily shoulder pain. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 2, 2021

Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours). Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities. Core Psilocybin Facilitation Skills (16 Hours). info@gl-lg.com

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

The Cannigma

DECEMBER 12, 2022

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Comparing psychedelics: dosing and consumption information. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Prior to joining Sesen Bio, Mr. Barbera served as the Vice President of Market Access at UroGen Pharma and played a critical role in the launch of the company’s first commercial product, Jelmyto ®. For more information, please visit the Company’s website at www.sesenbio.com.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

SEPTEMBER 24, 2019

We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”. “The ADDITIONAL INFORMATION. Lancet Neurol.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. For now, if you have access to quality CBD products, there’s no reason to prioritize CBG products. Easy access. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JUNE 11, 2019

Despite the recent legalization of cannabis, a framework for access to cannabis for medical purposes still exists, but under new regulations passed under the authority of the Cannabis Act. Kwon , 27 noted that common sense should inform awards for costs of future care. The court, citing Penner v. Silk 26 and Travis v.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45

The Cannigma

MARCH 12, 2021

At the end of the episode, Debbie Churgai, executive director of Americans for Safe Access, discusses the various ways that military veterans — who could very much benefit from medical cannabis — have difficulty accessing it and the ways that the Veterans Administration can address that issue. Produced by Michael Schaeffer Omer-Man.

Legalization 128

Legalization Patients Education Dispensary 128

The Cannigma

JANUARY 13, 2023

Russo concluded the evidence he examined “supports experimental protocols of cannabis usage in migraine treatment should go forward employing modern controlled clinical trials.” The first piece of information you genuinely need is the chemotype of your cannabis. Ethan Russo details the historical use of cannabis for migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. As sources of medical information, they are relatively under-researched. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

CannaMD

MARCH 8, 2021

1455 covers three major themes: medical marijuana advertising, THC potency/access to high-THC products, and administrative issues. Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. Food & Drug Association’s role in H.B. What is Florida House Bill 1455?

THC 116

THC Research and Development Treatment Patients 116

The Cannigma

APRIL 8, 2021

Listen & Subscribe: As both a regulated medicine and something people use for wellness and even recreation, the information gaps that exist for cannabis users are unprecedented. Any other medication and you’re lawfully entitled to speak to a pharmacist,” explains Dr. Codi Peterson, a clinical pharmacist and medical cannabis professional.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

MAY 13, 2019

Medical professionals want more information about medicinal cannabis before they start prescribing it to patients, a new study has found. In nearly every jurisdiction where medicinal cannabis is legal, at least one medical professional is required to sign off for a person to access it. Gardiner , Judith A. Kyle , Lisa M.

Medicine 45

Medicine Research and Development Clinical Trials Data 45